Serum Circulating miR-150 is a Predictor of Post-Acute Myocardial Infarction Heart Failure

Area of Science:

• Cardiology
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Ischemic heart disease and acute myocardial infarction (AMI) are increasing globally, often leading to poor prognosis and heart failure (HF).
• Predictive biomarkers for post-AMI HF are crucial for timely and effective treatment strategies.
• Current diagnostic methods may require enhancement for accurate HF prediction post-MI.

Purpose of the Study:

• To investigate the potential of serum circulating microRNAs (miRs), specifically miR-150, as a predictive biomarker for heart failure (HF) in patients post-acute myocardial infarction (AMI).
• To evaluate the diagnostic and prognostic value of miR-150, alone and in combination with established biomarkers like BNP, for predicting post-AMI HF.
• To identify independent predictors of post-AMI HF through multivariate analysis.

Main Methods:

• Recruitment of 54 post-AMI HF patients, 59 post-AMI non-HF patients, and 59 healthy controls.
• Screening of eight candidate miRs using real-time quantitative PCR, with a focus on serum miR-150 levels.
• Analysis of miR-150 association with ejection fraction (EF) and prediction accuracy using Receiver Operating Characteristic (ROC) curve analysis, including combination with BNP.

Main Results:

• Serum miR-150 levels were significantly lower in the post-AMI HF group compared to the post-AMI non-HF group (P < 0.001).
• miR-150 levels correlated with ejection fraction (EF) one year post-discharge (P < 0.001).
• ROC analysis showed miR-150 improved AUC to 0.764 (P < 0.001) for predicting post-AMI HF, with the combination of BNP and miR-150 achieving an AUC of 0.807 (P < 0.001).

Conclusions:

• Serum circulating miR-150 is a novel and independent biomarker for predicting heart failure following acute myocardial infarction (AMI).
• The combination of miR-150 and BNP offers enhanced predictive accuracy for post-AMI HF.
• Further large-scale prospective studies are warranted to validate the clinical utility of miR-150 in managing post-AMI patients.